

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptacmb1647

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 JAN 12 Match STN Content and Features to Your Information  
Needs, Quickly and Conveniently  
NEWS 3 JAN 25 Annual Reload of MEDLINE database  
NEWS 4 FEB 16 STN Express Maintenance Release, Version 8.4.2, Is  
Now Available for Download  
NEWS 5 FEB 16 Derwent World Patents Index (DWPI) Revises Indexing  
of Author Abstracts  
NEWS 6 FEB 16 New FASTA Display Formats Added to USGENE and PCTGEN  
NEWS 7 FEB 16 INPADOCDB and INPAFAMDB Enriched with New Content  
and Features  
NEWS 8 FEB 16 INSPEC Adding Its Own IPC codes and Author's E-mail  
Addresses  
NEWS 9 APR 02 CAS Registry Number Crossover Limits Increased to  
500,000 in Key STN Databases  
NEWS 10 APR 02 PATDPAFULL: Application and priority number formats  
enhanced  
NEWS 11 APR 02 DWPI: New display format ALLSTR available  
NEWS 12 APR 02 New Thesaurus Added to Derwent Databases for Smooth  
Sailing through U.S. Patent Codes  
NEWS 13 APR 02 EMBASE Adds Unique Records from MEDLINE, Expanding  
Coverage back to 1948  
NEWS 14 APR 07 CA/Caplus CLASS Display Streamlined with Removal of  
Pre-IPC 8 Data Fields  
NEWS 15 APR 07 50,000 World Traditional Medicine (WTM) Patents Now  
Available in Caplus  
NEWS 16 APR 07 MEDLINE Coverage Is Extended Back to 1947  
  
NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,  
AND CURRENT DISCOVER FILE IS DATED 15 JANUARY 2010.  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN customer  
agreement. This agreement limits use to scientific research. Use  
for software development or design, implementation of commercial  
gateways, or use of CAS and STN data in the building of commercial  
products is prohibited and may result in loss of user privileges  
and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 10:27:14 ON 06 MAY 2010

=> file medline biosis caplus embase  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.22	0.22

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 10:27:33 ON 06 MAY 2010

FILE 'BIOSIS' ENTERED AT 10:27:33 ON 06 MAY 2010

Copyright (c) 2010 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 10:27:33 ON 06 MAY 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 10:27:33 ON 06 MAY 2010

Copyright (c) 2010 Elsevier B.V. All rights reserved.

=> s Hruska K?/AU

L1 1433 HRUSKA K?/AU

=> s l1 and (morphogen and ACE(w)inhibitor)

L2 1 L1 AND (MORPHOGEN AND ACE(W) INHIBITOR)

=> McCartney J?/AU

MCCARTNEY IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).

=> s McCartney J?/AU

L3 662 MCCARTNEY J?/AU

=> s l3 and (morphogen and ACE(w)inhibitor)

L4 1 L3 AND (MORPHOGEN AND ACE(W) INHIBITOR)

=> s Charette M?/AU

L5 325 CHARETTE M?/AU

=> s l5 and (morphogen and ACE(w)inhibitor)

L6 1 L5 AND (MORPHOGEN AND ACE(W) INHIBITOR)

=> dis his

(FILE 'HOME' ENTERED AT 10:27:14 ON 06 MAY 2010)

FILE 'MEDLINE, BIOSIS, CAPLUS, EMBASE' ENTERED AT 10:27:33 ON 06 MAY 2010

L1 1433 S HRUSKA K?/AU

L2 1 S L1 AND (MORPHOGEN AND ACE(W)INHIBITOR)

L3 662 S MCCARTNEY J?/AU

L4 1 S L3 AND (MORPHOGEN AND ACE(W)INHIBITOR)

L5 325 S CHARETTE M?/AU

L6 1 S L5 AND (MORPHOGEN AND ACE(W)INHIBITOR)

=> dis ibib abs l2

L2 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:203626 CAPLUS

DOCUMENT NUMBER: 140:247061

TITLE: Conjoint administration of morphogens and

ACE inhibitors in treatment of  
chronic renal failure  
INVENTOR(S): Charette, Marc F.; Hruska, Keith A.;  
McCartney, John  
PATENT ASSIGNEE(S): Curis, Inc., USA; Washington University in St. Louis;  
Barnes-Jewish Hospital  
SOURCE: PCT Int. Appl., 295 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004019876	A2	20040311	WO 2003-US26923	20030828
WO 2004019876	A3	20060323		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2497048	A1	20040311	CA 2003-2497048	20030828
AU 2003268219	A1	20040319	AU 2003-268219	20030828
AU 2003268219	B2	20090924		
EP 1578360	A2	20050928	EP 2003-749170	20030828
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 20050272649	A1	20051208	US 2003-650326	20030828
JP 2006516020	T	20060615	JP 2004-531612	20030828
AU 2009250981	A1	20100114	AU 2009-250981	20091216
PRIORITY APPLN. INFO.:				
			US 2002-406431P	P 20020828
			AU 2003-268219	A3 20030828
			WO 2003-US26923	W 20030828

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention provides reagents and methods for the treatment, and pharmaceuticals for use in the prevention and/or treatment, of chronic renal failure and other renal disorders in subjects (particularly mammalian subjects) renal replacement therapy. The methods involve the conjoint administration of ACE (Angiotensin-Converting Enzyme) inhibitors or Angiotensin II Receptor Antagonists (AIIAs) with one or more OP/BMP family of proteins (morphogens, or inducers of morphogens, or agonists of the corresponding morphogen receptors, etc.). The invention also provides methods for implantation of renal cells induced with the conjoint administration of ACE inhibitors or AIIAs with those morphogens.

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

=> dis his

(FILE 'HOME' ENTERED AT 10:27:14 ON 06 MAY 2010)

FILE 'MEDLINE, BIOSIS, CAPLUS, EMBASE' ENTERED AT 10:27:33 ON 06 MAY 2010  
 L1 1433 S HRUSKA K7/AU  
 L2 1 S L1 AND (MORPHOGEN AND ACE(W)INHIBITOR)

L3 662 S MCCARTNEY J?/AU  
 L4 1 S L3 AND (MORPHOGEN AND ACE(W)INHIBITOR)  
 L5 325 S CHARETTE M?/AU  
 L6 1 S L5 AND (MORPHOGEN AND ACE(W)INHIBITOR)

=> dis ibib abs l4

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN  
 ACCESSION NUMBER: 2004:203626 CAPLUS  
 DOCUMENT NUMBER: 140:247061  
 TITLE: Conjoint administration of morphogens and  
 ACE inhibitors in treatment of  
 chronic renal failure  
 INVENTOR(S): Charette, Marc F.; Hruska, Keith A.; McCartney,  
 John  
 PATENT ASSIGNEE(S): Curis, Inc., USA; Washington University in St. Louis;  
 Barnes-Jewish Hospital  
 SOURCE: PCT Int. Appl., 295 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004019876	A2	20040311	WO 2003-US26923	20030828
WO 2004019876	A3	20060323		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2497048	A1	20040311	CA 2003-2497048	20030828
AU 2003268219	A1	20040319	AU 2003-268219	20030828
AU 2003268219	B2	20090924		
EP 1578360	A2	20050928	EP 2003-749170	20030828
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 20050272649	A1	20051208	US 2003-650326	20030828
JP 2006516020	T	20060615	JP 2004-531612	20030828
AU 2009250981	A1	20100114	AU 2009-250981	20091216
PRIORITY APPLN. INFO.:				
			US 2002-406431P	P 20020828
			AU 2003-268219	A3 20030828
			WO 2003-US26923	W 20030828

# ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention provides reagents and methods for the treatment, and pharmaceuticals for use in the prevention and/or treatment, of chronic renal failure and other renal disorders in subjects (particularly mammalian subjects) renal replacement therapy. The methods involve the conjoint administration of ACE (Angiotensin-Converting Enzyme) inhibitors or Angiotensin II Receptor Antagonists (AIIRAs) with one or more OP/BMP family of proteins (morphogens, or inducers of morphogens, or agonists of the corresponding morphogen receptors, etc.). The invention also provides methods for implantation of renal cells induced with the conjoint administration of ACE inhibitors or AIIRAs with those morphogens.

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD  
(3 CITINGS)

=> dis ibib abs 16

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN  
ACCESSION NUMBER: 2004:203626 CAPLUS  
DOCUMENT NUMBER: 140:247061  
TITLE: Conjoint administration of morphogens and  
ACE inhibitors in treatment of  
chronic renal failure  
INVENTOR(S): Charette, Marc F.; Hruska, Keith A.;  
McCartney, John  
PATENT ASSIGNEE(S): Curis, Inc., USA; Washington University in St. Louis;  
Barnes-Jewish Hospital  
SOURCE: PCT Int. Appl., 295 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004019876	A2	20040311	WO 2003-US26923	20030828
WO 2004019876	A3	20060323		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2497048	A1	20040311	CA 2003-2497048	20030828
AU 2003268219	A1	20040319	AU 2003-268219	20030828
AU 2003268219	B2	20090924		
EP 1578360	A2	20050928	EP 2003-749170	20030828
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
US 20050272649	A1	20051208	US 2003-650326	20030828
JP 2006516020	T	20060615	JP 2004-531612	20030828
AU 2009250981	A1	20100114	AU 2009-250981	20091216
PRIORITY APPLN. INFO.:			US 2002-406431P	P 20020828
			AU 2003-268219	A3 20030828
			WO 2003-US26923	W 20030828

# ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention provides reagents and methods for the treatment, and pharmaceuticals for use in the prevention and/or treatment, of chronic renal failure and other renal disorders in subjects (particularly mammalian subjects) renal replacement therapy. The methods involve the conjoint administration of ACE (Angiotensin-Converting Enzyme) inhibitors or Angiotensin II Receptor Antagonists (AIIARs) with one or more OP/BMP family of proteins (morphogens, or inducers of morphogens, or agonists of the corresponding morphogen receptors, etc.). The invention also provides methods for implantation of renal cells induced with the conjoint administration of ACE inhibitors or AIIARs with those morphogens.

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD

(3 CITINGS)

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF  
LOGOFF? (Y)/N/HOLD:y

(FILE 'HOME' ENTERED AT 10:27:14 ON 06 MAY 2010)

FILE 'MEDLINE, BIOSIS, CAPLUS, EMBASE' ENTERED AT 10:27:33 ON 06 MAY 2010

L1	1433	SEA	FILE=MFE	SPE=ON	ABB=ON	PLU=ON	HRUSKA K?/AU
L2	1	SEA	FILE=MFE	SPE=ON	ABB=ON	PLU=ON	L1 AND (MORPHOGEN AND
		ACE(W)	INHIBITOR)				
L3	662	SEA	FILE=MFE	SPE=ON	ABB=ON	PLU=ON	MCCARTNEY J?/AU
L4	1	SEA	FILE=MFE	SPE=ON	ABB=ON	PLU=ON	L3 AND (MORPHOGEN AND
		ACE(W)	INHIBITOR)				
L5	325	SEA	FILE=MFE	SPE=ON	ABB=ON	PLU=ON	CHARETTE M?/AU
L6	1	SEA	FILE=MFE	SPE=ON	ABB=ON	PLU=ON	L5 AND (MORPHOGEN AND
		ACE(W)	INHIBITOR)				
		DIS	IBIB ABS L2				
		DIS	IBIB ABS L4				
		DIS	IBIB ABS L6				

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	41.35	41.57
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-2.55	-2.55

STN INTERNATIONAL LOGOFF AT 10:30:21 ON 06 MAY 2010